Overcoming Solubility Challenges: Liposomal isoCoQ-Carbazole as a Promising Anti-Tumor Agent for Inoperable and Radiation-Insensitive cancers.
Diana LamaaCatherine CailleauJuliette VergnaudJulie MouginJérôme BignonMouâd AlamiElias FattalAbdallah HamzeNicolas TsapisPublished in: Chembiochem : a European journal of chemical biology (2024)
This study evaluated the potential of isoCoQ-Carbazole, a diheterocyclic analog of isoCA-4, as an anti-tumor agent. To overcome its low aqueous solubility, liposomes were developed as a delivery system for the compound. In vitro experiments showed that loaded liposomes exhibited similar activity to the free form on multiple human tumor cell lines. In vivo experiments using a palliative intratumoral injection chemotherapy approach further demonstrated that isoCoQ-Carbazole loaded liposomes significantly reduced tumor growth in a CA-4-resistant HT29 cell model, without inducing any observable toxicity or weight loss in the treated mice. These findings suggest that liposomal isoCoQ-Carbazole may hold promise as a potential therapeutic agent for the treatment of inoperable, radiation-insensitive cancers.
Keyphrases
- drug delivery
- weight loss
- locally advanced
- drug release
- cancer therapy
- endothelial cells
- bariatric surgery
- single cell
- oxidative stress
- palliative care
- radiation induced
- roux en y gastric bypass
- stem cells
- radiation therapy
- high fat diet induced
- cell therapy
- ultrasound guided
- big data
- rectal cancer
- advanced cancer
- bone marrow
- gastric bypass
- risk assessment
- metabolic syndrome
- replacement therapy
- body mass index
- smoking cessation